Literature DB >> 28748519

Obstetric antiphospholipid syndrome and long term arterial thrombosis risk.

Genady Drozdinsky1,2, Eran Hadar3,2, Anat Shmueli3,2, Rinat Gabbay-Benziv3,2, Shachaf Shiber4,5.   

Abstract

Antiphospholipid syndrome (APS) is classified as the association of a thrombotic event and/or obstetric morbidity in patients persistently positive for antiphospholipid antibodies and/or lupus anticoagulant. To evaluate the incidence of subsequent thrombosis among women diagnosed with purely obstetric APS. We retrospectively reviewed and collected demographic and clinical data from the computerized charts of all patients with obstetric APS, from 1992 to 2017. Eligibility criteria included all women diagnosed with APS, according to the 2006 revised criteria, for whom the clinical manifestations were purely obstetric. The primary endpoint was the occurrence of subsequent thromboembolic events, following diagnosis of obstetric APS. The study included 115 women diagnosed with obstetric APS. During the study's follow up period, 12 (10.4%) women developed thrombosis. Of the 12 women who developed thrombosis, 9 (75%) of the thrombotic events were arterial. The site of arterial thrombosis was cerebral in all cases. Venous thrombosis occurred in 3 (25%) women, including one in each of the following sites-pulmonary embolism, ovarian vein thrombosis and proximal leg deep vein thrombosis. Our data suggests that women with obstetric APS are at risk for subsequent long-term thrombosis, especially arterial cerebral events. We did not identify any clinical or laboratory unique features among women with obstetric APS who will eventually develop thrombosis.

Entities:  

Keywords:  Antiphospholipid syndrome; Obstetric; Stroke; Thrombosis

Mesh:

Year:  2017        PMID: 28748519     DOI: 10.1007/s11239-017-1526-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  16 in total

1.  High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.

Authors:  D Erkan; J T Merrill; Y Yazici; L Sammaritano; J P Buyon; M D Lockshin
Journal:  Arthritis Rheum       Date:  2001-06

2.  Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study.

Authors:  Jean-Christophe Gris; Sylvie Bouvier; Nicolas Molinari; Jean-Philippe Galanaud; Eva Cochery-Nouvellon; Erik Mercier; Pascale Fabbro-Peray; Jean-Pierre Balducchi; Pierre Marès; Isabelle Quéré; Michel Dauzat
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

3.  Practice Bulletin No. 132: Antiphospholipid syndrome.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

Review 4.  Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 5.  Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.

Authors:  Marianne Empson; Marissa Lassere; Jonathan C Craig; James R Scott
Journal:  Obstet Gynecol       Date:  2002-01       Impact factor: 7.661

Review 6.  Antiphospholipid syndrome.

Authors:  Guillermo Ruiz-Irastorza; Mark Crowther; Ware Branch; Munther A Khamashta
Journal:  Lancet       Date:  2010-09-06       Impact factor: 79.321

7.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Authors:  G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

8.  Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

Authors:  Rolf T Urbanus; Bob Siegerink; Mark Roest; Frits R Rosendaal; Philip G de Groot; Ale Algra
Journal:  Lancet Neurol       Date:  2009-09-25       Impact factor: 44.182

9.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Shannon M Bates; Ian A Greer; Ingrid Pabinger; Shoshanna Sofaer; Jack Hirsh
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Clinical consequences of antiphospholipid antibodies: an historic cohort study.

Authors:  R M Silver; M L Draper; J R Scott; J L Lyon; J Reading; D W Branch
Journal:  Obstet Gynecol       Date:  1994-03       Impact factor: 7.661

View more
  5 in total

1.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

2.  Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.

Authors:  Stanley Niznik; Micha J Rapoport; Orly Avnery; Aharon Lubetsky; Ronen Shavit; Martin H Ellis; Nancy Agmon-Levin
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

3.  Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.

Authors:  Hui Jiang; Chu-Han Wang; Nan Jiang; Jing Li; Chan-Yuan Wu; Qian Wang; Meng-Tao Li; Xin-Ping Tian; Jiu-Liang Zhao; Yan Zhao; Xiao-Feng Zeng
Journal:  Arthritis Res Ther       Date:  2021-05-08       Impact factor: 5.156

Review 4.  Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Ariadna Anunciación-Llunell; Joana Marques-Soares; Josep Pardos-Gea; Francesc Miró-Mur
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

5.  Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

Authors:  G R de Jesús; S Sciascia; D Andrade; M Barbhaiya; M Tektonidou; A Banzato; V Pengo; L Ji; P L Meroni; A Ugarte; H Cohen; D W Branch; L Andreoli; H M Belmont; P R Fortin; M Petri; E Rodriguez; R Cervera; J S Knight; T Atsumi; R Willis; I S Nascimento; R Rosa; D Erkan; R A Levy
Journal:  BJOG       Date:  2018-10-24       Impact factor: 6.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.